These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 8195874)

  • 1. Food and Drug Administration grants approval for 131I MIBG.
    Miller L
    J Nucl Med; 1994 Jun; 35(6):13N, 17N. PubMed ID: 8195874
    [No Abstract]   [Full Text] [Related]  

  • 2. Diagnostic and therapeutic uses of metaiodobenzylguanidine.
    Parisi MT; Hattner RS
    West J Med; 1992 Jul; 157(1):62-3. PubMed ID: 1413749
    [No Abstract]   [Full Text] [Related]  

  • 3. The treatment of neuroblastoma with [131I]MIBG at diagnosis.
    Troncone L; Rufini V; Luzi S; Mastrangelo R; Riccardi R
    Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):65-8. PubMed ID: 9002753
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Iodobenzylguanide-131 therapy as first choice in non-metastasized neuroblastoma].
    De Kraker J; Hoefnagel CA; Caron HN; Vos A; Bras J; Greve JC
    Ned Tijdschr Geneeskd; 1996 Oct; 140(40):1997-2000. PubMed ID: 8965930
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Clinical remission and reduction of malignant pheochromocytoma treated with iodine-131-meta-iodobenzylguanidine].
    Piñero A; Hernández A; Rodríguez JM; Parrilla P
    Med Clin (Barc); 1996 Nov; 107(19):755-6. PubMed ID: 9082096
    [No Abstract]   [Full Text] [Related]  

  • 6. Dosimetric models and S factors for radiation doses to the bladder wall in children receiving therapeutic iodine-131-MIBG.
    Bolster AA; Hilditch TE; Wheldon TE
    J Nucl Med; 1995 Aug; 36(8):1530-1. PubMed ID: 7629603
    [No Abstract]   [Full Text] [Related]  

  • 7. Therapeutic effect of m-[131I]- and m-[125I]iodobenzylguanidine on neuroblastoma multicellular tumor spheroids of different sizes.
    Weber W; Weber J; Senekowitsch-Schmidtke R
    Cancer Res; 1996 Dec; 56(23):5428-34. PubMed ID: 8968097
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment with meta-[131I]iodobenzylguanidine and cisplatin in stage IV neuroblastoma.
    Mastrangelo S; Tornesello A; Diociaiuti L; Riccardi R; Rufini V; Troncone L
    Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):69-71. PubMed ID: 9002754
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 131I-MIBG therapy of neural crest tumours (review).
    Troncone L; Rufini V
    Anticancer Res; 1997; 17(3B):1823-31. PubMed ID: 9179240
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of recurrent stage IV neuroblastomas with 131I-MIBG and HBO Six years follow-up.
    van der Kleij AJ; Voûte PA
    Strahlenther Onkol; 1996 Nov; 172 Suppl 2():28-9. PubMed ID: 8946044
    [No Abstract]   [Full Text] [Related]  

  • 11. [Carcinoid tumor metastases visualized by I-MIBG. Report of 5 cases].
    Mey P; Minier JF
    Ann Radiol (Paris); 1990; 33(4-5):237-9. PubMed ID: 2268126
    [No Abstract]   [Full Text] [Related]  

  • 12. Renal failure as a cause of false-positive on metaiodobenzilguanidine (MIBG) scan.
    Gallar P; Oliet A; Hernandez E; Vigil A; Ortega O
    Nephrol Dial Transplant; 1993; 8(5):481. PubMed ID: 8393560
    [No Abstract]   [Full Text] [Related]  

  • 13. [131I]MIBG as a first line treatment in advanced neuroblastoma.
    Hoefnagel CA; De Kraker J; Valdés Olmos RA; Voûte PA
    Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):61-4. PubMed ID: 9002752
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Therapeutic possibilities in metastatic pheochromocytoma].
    Vierhapper H; Raber W
    Zentralbl Chir; 1997; 122(6):494-7. PubMed ID: 9334119
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Radiochemical purity, at expiry, and radiochemical stability of iodine-131 labelled meta-iodobenzylguanidine concentrates for intravenous infusion.
    Wafelman AR; Hoefnagel CA; Maes RA; Beijnen JH
    Nuklearmedizin; 1996 Aug; 35(4):122-5. PubMed ID: 8784866
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Place of meta-[131I]iodobenzylguanidine in the treatment of neuroblastoma: the Genoa experience.
    Garaventa A; Pianca C; Conte M; Nigro M; De Bernardi B; Claudiani F; Stimamiglio P; Bertolazzi L; Cabria M; Villavecchia GP
    Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):58-60. PubMed ID: 9002751
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The ODAC Chronicles: Part 3. The FDA's philosophy and process for cancer drug evaluation and approval.
    Grillo-López AJ
    Expert Rev Anticancer Ther; 2005 Feb; 5(1):1-5. PubMed ID: 15757431
    [No Abstract]   [Full Text] [Related]  

  • 18. Cancer drug approval in the United States, Europe, and Japan.
    Milsted RA
    Adv Cancer Res; 2007; 96():371-91. PubMed ID: 17161686
    [No Abstract]   [Full Text] [Related]  

  • 19. A speedy approval.
    Schultz S
    US News World Rep; 2002 Aug 26-Sep 2; 133(8):26. PubMed ID: 12219556
    [No Abstract]   [Full Text] [Related]  

  • 20. The ODAC Chronicles: Part 4. Hurdles pre and post accelerated approval.
    Grillo-López AJ
    Expert Rev Anticancer Ther; 2005 Apr; 5(2):197-200. PubMed ID: 15877516
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.